Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q8WU67
UPID:
ABHD3_HUMAN
Alternative names:
Abhydrolase domain-containing protein 3
Alternative UPACC:
Q8WU67; B0YIV0; B7Z5C2; O43411
Background:
Phospholipase ABHD3, also known as Abhydrolase domain-containing protein 3, plays a crucial role in phospholipids remodeling. It exhibits a predominant phospholipase 1 activity, selectively cleaving myristate (C14)-containing phosphatidylcholines, primarily at the sn1 position. Additionally, ABHD3 may possess minor phospholipase 2 activity, targeting acyl groups at the sn2 position. Its ability to act on medium-chain-containing and oxidatively truncated phospholipids further underscores its biological significance.
Therapeutic significance:
Understanding the role of Phospholipase ABHD3 could open doors to potential therapeutic strategies.